Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma
- 24 July 2023
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 202 (6) , 1224-1227
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patientsLeukemia & Lymphoma, 2021
- Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum GuidelineBritish Journal of Haematology, 2021
- Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixaforHaematologica, 2020
- Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusionHaematologica, 2018
- How I manage red cell transfusions in patients with sickle cell diseaseBritish Journal of Haematology, 2018
- Racial disparities in treatment use for multiple myelomaCancer, 2017
- Increased blood viscosity and red blood cell aggregation in a patient with sickle cell anemia and smoldering myelomaAmerican Journal of Hematology, 2012
- Thalidomide therapy in a patient with thalassemia majorBlood Cells, Molecules, and Diseases, 2008
- Sickle Cell Anemia and Hematological NeoplasiasLeukemia & Lymphoma, 2002
- Fatal sickle cell crisis after granulocyte colony-stimulating factor administrationBlood, 2001